Following receipt of all required antitrust and regulatory approvals, Roche says it has finalized the acquisition of LumiraDx's Point of Care technology, a transaction for which an agreement had been signed at the end of 2023.

The acquired solution will complement the Swiss healthcare group's diagnostics portfolio in clinical chemistry, immunochemistry, coagulation and molecular, as well as multiple disease areas.

The LumiraDx platform and technology will help us expand the availability of tests, particularly in settings such as primary care and low- and middle-income countries", explains Matt Sause, CEO of Roche Diagnostics.

Copyright (c) 2024 CercleFinance.com. All rights reserved.